Physician profile
Rasheed A Balogun
NPI 1760511711
$23,590.14
in general payments reported to CMS, 2019-2025
12 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $33.15 · 2022: $9,739 · 2023: $569 · 2024: $617 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,254.96 |
| Food and Beverage | $1,377.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nipro Medical Corporation | $12,254.96 | 2025 | Hemodialysis System |
| Vifor Pharma, INC. | $9,400.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $671.87 | 2022-2024 | |
| Glaxosmithkline, LLC. | $325.02 | 2023-2024 | Benlysta, Jesduvroq, Arexvy |
| Novo Nordisk INC | $251.27 | 2019-2022 | |
| Cormedix INC. | $137.80 | 2024 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.33 | 2023 | |
| Genzyme Corporation | $113.04 | 2023 | |
| Alexion Pharmaceuticals, INC. | $109.39 | 2025 | |
| Fresenius USA Marketing, INC. | $86.25 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $83.08 | 2025 | |
| Nxstage Medical, INC. | $33.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheed Balogun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.